Combination therapy with moderate-intensity atorvastatin and ezetimibe versus high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability.
Seung-Jun LeeJae Hong JooSohee ParkChoongki KimDong-Woo ChoiYong-Joon LeeSung-Jin HongChul-Min AhnJung-Sun KimByeong-Keuk KimYoung-Guk KoDonghoon ChoiYangsoo JangChung-Mo NamMeyong-Ki HongPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
In clinical practice, a combined lipid-lowering approach utilizing ezetimibe and moderate-intensity atorvastatin was correlated with favorable clinical outcomes, drug compliance, and a reduced incidence of new-onset diabetes requiring medications in patients treated with DES implantation. Trial registration: ClinicalTrial.gov (NCT04715594).
Keyphrases
- high intensity
- combination therapy
- percutaneous coronary intervention
- clinical practice
- resistance training
- type diabetes
- st segment elevation myocardial infarction
- primary care
- acute coronary syndrome
- coronary artery disease
- study protocol
- healthcare
- risk factors
- clinical trial
- st elevation myocardial infarction
- phase iii
- coronary artery bypass grafting
- glycemic control
- randomized controlled trial
- fatty acid
- open label
- heart failure
- adipose tissue
- emergency department
- metabolic syndrome
- drug induced